Results 151 to 160 of about 8,893 (235)

Variation in uptake of sodium glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor analogues in adults with type 2 diabetes at high cardiovascular risk

Purpose: We quantified variation in the uptake of sodium-glucose co-transporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor analogues (GLP-1RA) across sociodemographic, behavioural and clinical characteristics of people with type 2 ...
Day, RO , de Oliveira Costa, J , Falster, MO , Gibson, AA, Greenfield, JR , Havard, A, Lin, J , Milder, TY, Morton, JI, Neuen, BL, Pearson, SA , Sacre, JW   +11 more
core   +1 more source

GLP-1RAs in patients with psoriasis

Hormones
Ioanna A. Paschou, Evangelia Sali, Stavroula A. Paschou, Theodora Psaltopoulou, Electra Nicolaidou, Alexander J. Stratigos   +5 more
openaire   +3 more sources

Decreased risk of post-thyroidectomy hypocalcemia with history of GLP-1RA use. [PDF]

J Endocr Soc
Ayo-Ajibola O, Jung T, Razura DE, Gallagher TJ, Lin ME, Angell TE, Kwon DI.   +6 more
europepmc   +1 more source

Cost-Effectiveness of Liraglutide Versus Dapagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus in the UK [PDF]

, 2017

core   +1 more source

GLP-1RA precision medicine in people with type 2 diabetes: current insights and future prospects. [PDF]

J Clin Invest
Cardoso P, Dennis JM, Pearson ER.
europepmc   +1 more source

Endogenous GLP-1 mediates postprandial reductions in activation in central reward and satiety areas in patients with type 2 diabetes [PDF]

core   +1 more source

The Proteomic Analysis of Intermittent Fasting Alone or with GLP-1RA in NAFLD Rats. [PDF]

Diabetes Metab Syndr Obes
Shao Y, Xu S, Ma Y, Zhang J, Guo X, Zhang T, Yuan G.   +6 more
europepmc   +1 more source

Evaluating Suicidal Risk in GLP-1RA Therapy: An Umbrella Review of Meta-Analytic Evidence. [PDF]

Healthcare (Basel)
Ștefănescu C, Bratu EA, Pelin AM, Boroi D, Crecan-Suciu BD, Ștefănescu V.   +5 more
europepmc   +1 more source

SGLT2 inhibitors, but not GLP-1 receptor agonists, reduce incidence of gout in people living with type 2 diabetes across the therapeutic spectrum

Purpose: This study aimed to evaluate the relative association between sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1Ra) with the incidence of gout in patients with type 2 diabetes (T2D) using real-
Alam, Uazman, Anson , Matthew, Cuthbertson, Daniel J., Henney, Alexander, Ibarburu, Gema H., Lip , Gregory Y.H, Preston, Frank G, Riley, David R, Zhao, Sizheng   +8 more
core   +3 more sources

Improving nutritional assessment in GLP-1RA therapy: Beyond self-reports to equitable interventions. [PDF]

Obes Pillars
Aphale P, Shekhar H, Dokania S.
europepmc   +1 more source